ArticleJournal of managed care & specialty pharmacy2021
Use of real-world evidence in economic assessments of pharmaceuticals in the United States.
Article in Journal of managed care & specialty pharmacy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Real-world data: a comprehensive literature review on the barriers, challenges, and opportunities associated with their inclusion in the health technology assessment process.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2024Pooled it
- Use of RWD in the assessment of economic evaluations of innovative health products: lessons learned from the French National Authority for health (HAS).International journal of technology assessment in health care · 2026Article
- Real-world evidence to support health technology assessment and payer decision making: is it now or never?International journal of technology assessment in health care · 2025Article
- Calibration of transition probabilities to model survival of adjuvant trastuzumab for early breast cancer in Indonesia.International journal of technology assessment in health care · 2025Article
- Payer perceptions on the use of economic models in oncology decision making.Journal of managed care & specialty pharmacy · 2021Article
- "It's Time to Represent": shifting the paradigm to improve the quality of inputs into value assessment frameworks.Journal of managed care & specialty pharmacy · 2021Article
- The use of real-world evidence in ICER's scoping process and clinical evidence assessments.Journal of managed care & specialty pharmacy · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.